Inclusion Criteria:

- Patients must have a histologically or cytologically confirmed malignant solid
tumour.

- Progression or recurrence of the tumour radiologically established or confirmed
within the 4 weeks prior to inclusion.

- Disease must be considered refractory to any line of conventional therapy or for
which no effective conventional treatment exists.

- Age: ≥4 to 21 years of age at study entry

- Life expectancy: at least 8 weeks

- ECOG Performance status ≤ 1 or Lansky-Play Scale ≥ 70%

- Written informed consent of parent/guardian and patient assent

- Wash out of 4 weeks in case of prior chemotherapy, 6 weeks if treatment included
nitrosoureas, 2 weeks in case of vincristine alone; 6 weeks in case of prior
radiotherapy (except palliative radiotherapy on non measurable lesions).

- Patients must have recovered from the acute toxic effects of all prior therapy before
enrolment into the study

- Able to comply with scheduled follow-up and with management of toxicity

- All patients with reproductive potential must practice an effective method of birth
control while on study.

- Female patients aged > 12 years must have a negative pregnancy test within 7 days
before study treatment.

- Capable of swallowing oral medication

Exclusion Criteria:

- Pregnant and breast feeding women.

- Uncontrolled intercurrent illness or active infection

- Inability to swallow oral medication.

- Patients on anticonvulsants will be allowed on study